A randomized trial of dietary sodium restriction in CKD

Emma J McMahon, Judith D Bauer, Carmel M Hawley, Nicole M Isbel, Michael Stowasser, David W Johnson, Katrina L Campbell

Research output: Contribution to journalArticleResearchpeer-review

133 Citations (Scopus)

Abstract

There is a paucity of quality evidence regarding the effects of sodium restriction in patients with CKD, particularly in patients with pre-end stage CKD, where controlling modifiable risk factors may be especially important for delaying CKD progression and cardiovascular events. We conducted a double-blind placebo-controlled randomized crossover trial assessing the effects of high versus low sodium intake on ambulatory BP, 24-hour protein and albumin excretion, fluid status (body composition monitor), renin and aldosterone levels, and arterial stiffness (pulse wave velocity and augmentation index) in 20 adult patients with hypertensive stage 3-4 CKD as phase 1 of the LowSALT CKD study. Overall, salt restriction resulted in statistically significant and clinically important reductions in BP (mean reduction of systolic/diastolic BP, 10/4 mm Hg; 95% confidence interval, 5 to 15 /1 to 6 mm Hg), extracellular fluid volume, albuminuria, and proteinuria in patients with moderate-to-severe CKD. The magnitude of change was more pronounced than the magnitude reported in patients without CKD, suggesting that patients with CKD are particularly salt sensitive. Although studies with longer intervention times and larger sample sizes are needed to confirm these benefits, this study indicates that sodium restriction should be emphasized in the management of patients with CKD as a means to reduce cardiovascular risk and risk for CKD progression.

Original languageEnglish
Pages (from-to)2096-103
Number of pages8
JournalJournal of the American Society of Nephrology : JASN
Volume24
Issue number12
DOIs
Publication statusPublished - Dec 2013
Externally publishedYes

Fingerprint

Dietary Sodium
Sodium
Salts
Pulse Wave Analysis
Vascular Stiffness
Albuminuria
Extracellular Fluid
Body Composition
Aldosterone
Proteinuria
Renin
Sample Size
Cross-Over Studies
Albumins
Placebos
Confidence Intervals

Cite this

McMahon, E. J., Bauer, J. D., Hawley, C. M., Isbel, N. M., Stowasser, M., Johnson, D. W., & Campbell, K. L. (2013). A randomized trial of dietary sodium restriction in CKD. Journal of the American Society of Nephrology : JASN, 24(12), 2096-103. https://doi.org/10.1681/ASN.2013030285
McMahon, Emma J ; Bauer, Judith D ; Hawley, Carmel M ; Isbel, Nicole M ; Stowasser, Michael ; Johnson, David W ; Campbell, Katrina L. / A randomized trial of dietary sodium restriction in CKD. In: Journal of the American Society of Nephrology : JASN. 2013 ; Vol. 24, No. 12. pp. 2096-103.
@article{8c641598519f4b939476158c114a2261,
title = "A randomized trial of dietary sodium restriction in CKD",
abstract = "There is a paucity of quality evidence regarding the effects of sodium restriction in patients with CKD, particularly in patients with pre-end stage CKD, where controlling modifiable risk factors may be especially important for delaying CKD progression and cardiovascular events. We conducted a double-blind placebo-controlled randomized crossover trial assessing the effects of high versus low sodium intake on ambulatory BP, 24-hour protein and albumin excretion, fluid status (body composition monitor), renin and aldosterone levels, and arterial stiffness (pulse wave velocity and augmentation index) in 20 adult patients with hypertensive stage 3-4 CKD as phase 1 of the LowSALT CKD study. Overall, salt restriction resulted in statistically significant and clinically important reductions in BP (mean reduction of systolic/diastolic BP, 10/4 mm Hg; 95{\%} confidence interval, 5 to 15 /1 to 6 mm Hg), extracellular fluid volume, albuminuria, and proteinuria in patients with moderate-to-severe CKD. The magnitude of change was more pronounced than the magnitude reported in patients without CKD, suggesting that patients with CKD are particularly salt sensitive. Although studies with longer intervention times and larger sample sizes are needed to confirm these benefits, this study indicates that sodium restriction should be emphasized in the management of patients with CKD as a means to reduce cardiovascular risk and risk for CKD progression.",
author = "McMahon, {Emma J} and Bauer, {Judith D} and Hawley, {Carmel M} and Isbel, {Nicole M} and Michael Stowasser and Johnson, {David W} and Campbell, {Katrina L}",
year = "2013",
month = "12",
doi = "10.1681/ASN.2013030285",
language = "English",
volume = "24",
pages = "2096--103",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

McMahon, EJ, Bauer, JD, Hawley, CM, Isbel, NM, Stowasser, M, Johnson, DW & Campbell, KL 2013, 'A randomized trial of dietary sodium restriction in CKD' Journal of the American Society of Nephrology : JASN, vol. 24, no. 12, pp. 2096-103. https://doi.org/10.1681/ASN.2013030285

A randomized trial of dietary sodium restriction in CKD. / McMahon, Emma J; Bauer, Judith D; Hawley, Carmel M; Isbel, Nicole M; Stowasser, Michael; Johnson, David W; Campbell, Katrina L.

In: Journal of the American Society of Nephrology : JASN, Vol. 24, No. 12, 12.2013, p. 2096-103.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A randomized trial of dietary sodium restriction in CKD

AU - McMahon, Emma J

AU - Bauer, Judith D

AU - Hawley, Carmel M

AU - Isbel, Nicole M

AU - Stowasser, Michael

AU - Johnson, David W

AU - Campbell, Katrina L

PY - 2013/12

Y1 - 2013/12

N2 - There is a paucity of quality evidence regarding the effects of sodium restriction in patients with CKD, particularly in patients with pre-end stage CKD, where controlling modifiable risk factors may be especially important for delaying CKD progression and cardiovascular events. We conducted a double-blind placebo-controlled randomized crossover trial assessing the effects of high versus low sodium intake on ambulatory BP, 24-hour protein and albumin excretion, fluid status (body composition monitor), renin and aldosterone levels, and arterial stiffness (pulse wave velocity and augmentation index) in 20 adult patients with hypertensive stage 3-4 CKD as phase 1 of the LowSALT CKD study. Overall, salt restriction resulted in statistically significant and clinically important reductions in BP (mean reduction of systolic/diastolic BP, 10/4 mm Hg; 95% confidence interval, 5 to 15 /1 to 6 mm Hg), extracellular fluid volume, albuminuria, and proteinuria in patients with moderate-to-severe CKD. The magnitude of change was more pronounced than the magnitude reported in patients without CKD, suggesting that patients with CKD are particularly salt sensitive. Although studies with longer intervention times and larger sample sizes are needed to confirm these benefits, this study indicates that sodium restriction should be emphasized in the management of patients with CKD as a means to reduce cardiovascular risk and risk for CKD progression.

AB - There is a paucity of quality evidence regarding the effects of sodium restriction in patients with CKD, particularly in patients with pre-end stage CKD, where controlling modifiable risk factors may be especially important for delaying CKD progression and cardiovascular events. We conducted a double-blind placebo-controlled randomized crossover trial assessing the effects of high versus low sodium intake on ambulatory BP, 24-hour protein and albumin excretion, fluid status (body composition monitor), renin and aldosterone levels, and arterial stiffness (pulse wave velocity and augmentation index) in 20 adult patients with hypertensive stage 3-4 CKD as phase 1 of the LowSALT CKD study. Overall, salt restriction resulted in statistically significant and clinically important reductions in BP (mean reduction of systolic/diastolic BP, 10/4 mm Hg; 95% confidence interval, 5 to 15 /1 to 6 mm Hg), extracellular fluid volume, albuminuria, and proteinuria in patients with moderate-to-severe CKD. The magnitude of change was more pronounced than the magnitude reported in patients without CKD, suggesting that patients with CKD are particularly salt sensitive. Although studies with longer intervention times and larger sample sizes are needed to confirm these benefits, this study indicates that sodium restriction should be emphasized in the management of patients with CKD as a means to reduce cardiovascular risk and risk for CKD progression.

U2 - 10.1681/ASN.2013030285

DO - 10.1681/ASN.2013030285

M3 - Article

VL - 24

SP - 2096

EP - 2103

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 12

ER -

McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW et al. A randomized trial of dietary sodium restriction in CKD. Journal of the American Society of Nephrology : JASN. 2013 Dec;24(12):2096-103. https://doi.org/10.1681/ASN.2013030285